JNJ Q2 2026 revenue up 6.6% to $25.3B; adjusted EPS $2.90 (+4.7%)

JOHNSON & JOHNSON

Q2 sales $25,310M (+6.6% operational, +1.0% currency); GAAP net earnings $5,534M (-0.1%).
GAAP diluted EPS $2.27 (-0.9%); adjusted diluted EPS $2.90 (+4.7%).
Innovative Medicine sales $16,384M (+7.8%); MedTech $8,926M (+4.5%).
US sales $14,533M (+7.3%); International $10,777M (+5.7%).

item 2.02 item 9.01

JOHNSON & JOHNSON filing history →

Source: SEC EDGAR

accession 0000200406-26-000146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.